Open an account

Kenvue

KVUE · NYSE

$19.28+$0.41 (+2.17%)TodayMarket closed ·
Prev close $18.87

About KVUE

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. The company is headquartered in Summit, New Jersey and currently employs 21,780 full-time employees. The company went IPO on 2023-05-04. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

Employees
21,780
Headquarters
Summit, New Jersey
Listed
May 4, 2023
Sector
Consumer Staples
Industry
Personal Care Products
Website
kenvue.com

KVUE key statistics

Market cap
37.03B
Price-earnings ratio
21.69
Dividend yield
4.39%
Average volume
19.93M
Volume
21.96M
Open price
$18.97
High today
$19.30
Low today
$18.95
52 Week high
$20.13
52 Week low
$14.02

Kenvue (KVUE) at a glance

Kenvue (KVUE) last traded at $19.28, with a market cap of 37.03B, a price-to-earnings ratio of 21.69 and a dividend yield of 4.39%.

Today the stock has traded between $18.95 and $19.30. The current price is 1.7% above the day's low and 0.1% below its high.

Volume so far is 21.96M shares, in line with the average of 19.93M shares a day.

Over the past year Kenvue has ranged from $14.02 to $20.13, and now sits 86% of the way up that range.

Kenvue met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.31 per share against an estimate of $0.3256.

The average analyst price target is $19.72, 2.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 5 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 15 analystsAvg $19.72
Low
$18.18
Now
$19.28
High
$23.10

KVUE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 7.8% on average.

  1. Q3 FY24: reported $0.28 per share against an estimate of $0.2793
  2. Q4 FY24: reported $0.26 per share against an estimate of $0.2632
  3. Q1 FY25: reported $0.24 per share against an estimate of $0.2329
  4. Q2 FY25: reported $0.29 per share against an estimate of $0.2882
  5. Q3 FY25: reported $0.28 per share against an estimate of $0.2705
  6. Q4 FY25: reported $0.27 per share against an estimate of $0.2256
  7. Q1 FY26: reported $0.32 per share against an estimate of $0.2675
  8. Q2 FY26: reported $0.31 per share against an estimate of $0.3256

KVUE news

  • 'Kimberly-Clark Readies Bond Sale Ahead of Tylenol Maker Purchase' - Bloomberg

  • Lekha Gupta

    Huggies Maker Kimberly-Clark Sticks To 2026 Profit Outlook

  • Press releasePRNewswire

    Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers

  • Press releasePRNewswire

    Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team

  • Press releaseBusiness Wire

    LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion

  • Press releaseBusiness Wire

    Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair

  • Press releasePRNewswire

    Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes

  • Vandana Singh

    Kimberly-Clark May Sell Assets to Save Its $40 Billion Kenvue Deal: Report

Similar companies

Companies in the same industry as Kenvue

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.